Document:

EX-10.21

 Exhibit 10.21 

LOAN AND LEASE AGREEMENT 

Dated as of December 20, 2013 

the “Effective Date” 

by and between 
 ESSEX CAPITAL
CORPORATION 
 as “Essex” 

and 
 REVANCE THERAPEUTICS, INC.

 as “Company” 

TOTAL CREDIT AMOUNT: Up to $10,800,000 
  

			
	Loan Terms:	  	Maturity 12 months term from Effective Date
	 Interest:
	  	11.5% per annum before IPO; 10.375% after IPO
	 Loan Conversion to Lease Date:
	  	Title transfer of Equipment
	 Lease Term:
	  	36 months

 Company wishes to acquire certain equipment. Essex is willing to finance that acquisition by lending money to Company to build
out and install that equipment and, upon Company’s acceptance of the equipment, by purchasing that equipment and leasing it to Company. The information set forth above is subject to the terms and conditions set forth in the balance of this
Agreement. The parties agree as follows: 

  
 1. 

 1. Advance and Payments. 

(a) Advances. Company may request one or more advances (each, an “Advance” and collectively, the
“Advances”), up to the aggregate principal amount of up to $10,800,000 (or such other amount as may be agreed to in writing by Essex and Company), with an initial Advance in the amount of $2,500,000 to be made within three business
days of the date hereof (the “Initial Advance”), a second Advance in the amount of $2,500,000 to be made no later than January 28, 2014 (the “Second Advance”),and additional Advances to be made based on the
advancement schedule set forth in Schedule I attached hereto (or on such other dates or such other amounts as may be agreed to in writing by Essex and Company) to complete the production and installation of the Company’s RT001 commercial
fill/finish line and the equipment identified on Exhibit A-1 (the “Ima Life Equipment”) and on Exhibit A-2 (the “Seidenader Equipment” and collectively with the Ima Life Equipment, the “Equipment”).
Company shall use the proceeds of each Advance to pay obligations incurred in connection with acquisition and installation of the Equipment, as set forth in more detail below.  

(b) Conditions to Advances. Essex’s obligation to make the Initial Advance is subject to (A) the delivery of a Note and
Warrant (each as defined below) concurrently with the execution of this Agreement and (B) consents from Hercules Technology Growth Capital, Inc. (“Hercules”) and Essex Woodlands Health Ventures Fund VIII, L.P. and NovaQuest
Pharma Opportunities Fund III, L.P. (“Bridge Lenders”) reasonably satisfactory to Essex. Company’s obligation to enter into this Agreement is subject to Essex’s delivery of subordination agreements with Hercules and the
Bridge Lenders (the “Subordination Agreements”). Essex’s obligation to make each Advance after the Initial Advance is subject to the satisfaction of the following conditions:  

(i) Company’s delivery to Essex of a written request for an Advance, in substantially similar form as Exhibit G attached hereto
(the “Advance Request”); 
 (ii) invoice(s) from vendor(s) (individually, a “Vendor”) in
connection with the applicable Equipment or other evidence reasonably satisfactory to Essex that Company has incurred or paid obligations to one or more Vendors;  

(iii) solely with respect to the Second Advance, an Acknowledgement of Financing and Security Interest by Ima Life in form and
substance reasonably satisfactory to Essex; and 
 (iv) no Event of Default (as hereinafter defined) or other event which,
with notice or the passing of time, would become an Event of Default, shall have occurred and be then continuing. 
 (c) Timing of
Advances. For each Advance other than the Initial Advance or the Second Advance, Company may request any Advance only within 90 days following the invoice date for the portion of Equipment corresponding to the applicable Advance as set forth on
Schedule I (the “Advance Period”). Essex shall make each Advance to Company within 21 days of Company’s delivery of the Advance Request and the other items listed in clause (b) above. Company shall endeavor to provide
Essex with copies of all invoices from the Vendors within 10 days of the Company’s receipt of such invoice from the applicable Vendor. 

(d) Delivery of Notes; Warrants. Concurrently with any Advance made by Essex, Company shall deliver to Essex an executed secured
promissory note in substantially the form of Exhibit B (each, a “Note”) and an executed warrant in substantially the form attached to this Agreement as Exhibit C (the “Warrant”); 

(e) Warrant Grants if Advance Not Made If, following the delivery of the applicable invoice(s) from the Vendor to Company, Company fails
to request an Advance during the relevant Advance Period, then Company will forfeit the right to request such Advance; and Company will issue a Warrant to Essex on the last day of such Advance Period with the number of Warrant Shares (as defined in
the Warrant) determined based on the principal amount of the applicable Advance set forth in Schedule I. Notwithstanding the foregoing, no Warrant shall be issued to Essex if an Advance is requested by the Company but not made by Essex by the last
day of the corresponding Advance Period following the Company’s satisfaction of all conditions to such Advance as set forth in this Agreement. 

  
 2. 

 (f) Interest. Company shall pay interest on the outstanding principal balance of the
Advances at a rate per annum equal to 11.5% at any time before the effectiveness of the Company’s initial public offering of its common stock (the “IPO”) and 10.375% from and after the effective date of the IPO. Interest shall
be calculated on the basis of a 360-day year for the actual number of days elapsed, shall accrue from the date of an Advance and continue until such Advance has been repaid, and shall be payable in arrears on the first day of each month until such
Advance has been repaid. Any partial month shall be prorated on the basis of a 30-day month based on the actual number of days outstanding. After the occurrence and during the continuance of any Event of Default, the interest rate shall increase to
a rate per annum equal to 15.0%. In no event shall the interest rate payable exceed the maximum rate of interest permitted to be charged under applicable law. 

(g) Payments. The outstanding principal amount of each Note, along with all accrued and unpaid interest on such amount, is due and
payable on the first anniversary of the Effective Date (or such later date as may be agreed to in writing by Essex and Company). All payments made to Essex shall be made via wire transfer per wire transfer instructions separately provided by Essex
to Company. Company may prepay all or any part of the Advances only with the prior written consent of Essex. 
 2. Sale and
Leaseback.  
 (a) Sale. Upon acceptance by Company of the fully operational Seidenader Equipment or Ima Life Equipment
from the applicable Vendor, Company will sell, and Essex will purchase all or a portion of such Equipment with respect to which the original invoiced amounts equal to the total aggregate principal amount of the Advances made by Essex with respect to
such Equipment. The Equipment so sold by Company to Essex is referred to as the “Purchased Equipment,” and the purchase price for the Purchased Equipment shall be equal to the total aggregate principal amount of the Advances made by
Essex with respect to such Equipment. Essex shall pay such purchase price by delivering to Company all of the original Notes representing such Advances for cancellation. Essex’s obligation to purchase the Purchased Equipment is subject to the
satisfaction of the following conditions:  
 (i) Company’s delivery to Essex of an executed bill of sale in
substantially the form of Exhibit D; 
 (ii) Company’s delivery of assurances reasonably satisfactory to Essex that Buyer
is transferring good and marketable title to the Purchased Equipment, free and clear of all liens and encumbrances; 
 (iii)
Company’s delivery to Essex of an executed Lease (as defined below) and the other documents contemplated by Section 2(b); and 

(iv) no Event of Default or other event which, with notice or the passing of time, would become an Event of Default hereunder or under
the Lease, shall have occurred and be then continuing.  
 (b) Leases. Concurrently with each of the two sales described in
Section 2(a), Company and Essex shall execute a Commercial Lease Agreement in respect of the Purchased Equipment with respect to such sale (each, a “Lease”) in substantially the form attached to this Agreement as Exhibit E. The
term of each Lease of such Purchased Equipment to Company shall be 36 months from the date of the applicable sale and leaseback. The monthly lease payments shall be calculated by Essex based on the total purchase price for such Purchased Equipment
and a money factor equivalent to an interest rate of 10.375% per annum. By way of illustration, if the total purchase price for the Seidenader Equipment purchased by Essex is $1,229,264, the total monthly lease payment would be $39,881.67. In
connection with, and as a condition to, the execution of each Lease by Essex, Company shall provide Essex with an executed landlord’s waiver with respect to each location at which Equipment is installed, in substantially the form attached to
this Agreement as Exhibit F (or as such waiver may be revised or modified with the consent of Essex). 
 (c) Taxes. Company
shall be responsible for the payment of any and all sales and use taxes relating to the Equipment, including any such taxes relating to the purchase of the Purchased Equipment by Essex or their lease by Essex to Company. 

  
 3. 

 3. Security Interest. To secure its obligations under each Note, Company grants Essex a
security interest in the Collateral, as defined on the date hereof in the Loan and Security Agreement by and between Company and Hercules dated as of September 20, 2011 and as amended from time to time (the “Hercules Loan
Agreement”), and referred to herein as the “Collateral”; provided however, the Collateral shall not include any copyrights, patents, trademarks, servicemarks and applications therefor, or any other intellectual property
rights, now owned or hereafter acquired, or any claims for damages by way of any past, present and future infringement of any of the foregoing. Company authorizes Essex to execute such documents and file applicable financing statements and take such
actions as Essex reasonably deems appropriate from time to time to perfect or continue the security interest granted hereunder. Notwithstanding the foregoing, on the date the sale and leaseback is consummated with respect to the applicable Purchased
Equipment, all obligations under the applicable Notes shall be fully satisfied and shall be of no further force and effect. Upon the completion of all sale and leaseback transactions contemplated in Section 2(a), the obligations on this
Agreement shall automatically terminate and be of no further force and effect and any security interest in favor of Essex with respect to securing Company’s obligations for such Purchased Equipment shall be governed solely by the terms set
forth in the applicable Lease and no longer be secured by the Collateral, and Essex authorizes Company to execute such documents and take such actions as Company reasonably deems appropriate from time to time to evidence the termination of the
security interest granted hereunder with respect to all Collateral other than the Purchased Equipment. 
 4. Representations, Warranties
and Covenants. Company represents and warrants to Essex as of the date hereof, and further covenants, as follows: 
 (a)
Authorization; No Conflicts. The execution, delivery and performance by Company of this Agreement, and all other documents contemplated hereby have been duly and validly authorized by all necessary corporate action. This Agreement has been duly
and validly executed and delivered by Company and constitutes a legal, valid and binding obligation of Company, enforceable against Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium and other similar laws and equitable principles relating to or limiting creditors’ rights generally. The execution, delivery and performance of by Company of this Agreement and the execution, delivery and performance
of any related agreements or transactions by Company will not violate, or constitute a breach or default (whether upon lapse of time and/or the occurrence of any act or event or otherwise) under, the Certificate of Incorporation or bylaws of Company
or any material agreement or instrument which is binding upon Company or its property, or violate any statute or other law, rule, regulation, or interpretation of any governmental entity. Company has obtained all approvals and consents required to
be obtained from, or any notices, statements or other communications required to be filed with or delivered to, any governmental entity or any other person or entity necessary for the transactions contemplated hereby. 

(b) State of Incorporation; Places of Business; Locations of Collateral. Company is duly organized, validly existing and in good
standing under the laws of Delaware. Company is qualified to do business as a foreign corporation in California and in each other state where the failure to be so qualified would have a material adverse effect on the Company. The Collateral is, and
will continue to be, located in California. 
 (c) Financial Condition, Statements and Reports. All financial statements provided to
Essex by Company (i) have been prepared in accordance with generally accepted accounting principles, consistently applied (“GAAP”) and (ii) fairly present the financial condition and results of operations of Company on the
dates and for the periods therein indicated. All material liabilities of Company are disclosed in such financial statements. 
 (d)
Title to Collateral; Liens. Company is now, and will at all times in the future be, the sole owner of all the Collateral (subject to Permitted Transfers (as defined on the date hereof in the Hercules Loan Agreement). The Collateral now is and
will remain free and clear of any and all liens, security interests and adverse claims, except for the security interests of Hercules and the Bridge Lenders and Permitted Liens (as defined in the Hercules Loan Agreement on the date hereof). Essex
now has, and will continue to have, a perfected and enforceable security interest in all of the Collateral, subject only to the security interests of Hercules and the Bridge Lenders and Permitted Liens. Company will not grant or permit to exist any
further liens or security interests in the Collateral (other than Permitted Liens as defined in the Hercules Loan Agreement on the date hereof) that are prior to or on par with those of Essex and will at all times defend Essex and the Collateral
against any such liens or claims of others. Company will not incur any secured Subordinated Debt (as defined in the Hercules Loan Agreement on the date hereof) after the date hereof without the prior written consent of Essex. 

  
 4. 

 (e) Litigation. Except as previously disclosed in writing to Essex, there is no claim,
suit, litigation, proceeding or investigation pending or (to best of Company’s knowledge) threatened in writing by or against or affecting Company in any court or before any governmental entity which may reasonably be excepted to have, either
separately or in the aggregate, a material adverse effect on the Company. Company will promptly inform Essex in writing of any such claim, proceeding, litigation or investigation in the future threatened in writing or instituted by or against
Company. 
 (f) Use of Proceeds. Proceeds of the Advances shall be used solely for the purpose set forth in Section 1(a). 

(g) Documents. Company has provided Essex with copies of all material agreements with each of Vendors, and with respect to indebtedness
owing to Hercules and the Bridge Lenders. Company will provide Essex with copies of all invoices and other documents received from any Vendor in connection with any Advance. All such documents provided, or to be provided, by Company to Essex are and
will be true, complete and correct in all material respects. Company will provide Essex with copies of any written notices of events of default from Hercules or the Bridge Lenders, within five business days of receipt by Company. 

(h) Phase 2b. Prior to the date hereof, the Company has provided to Essex evidence of positive data relating to the second cohort of the
Company’s Phase 2b clinical trial of RT001. 
 (i) Other Financing. Company covenants and agrees that it shall not use any
proceeds received from its equity financings or any third party financing arrangement to finance the amounts set forth on Schedule I without the prior written consent of Essex. 

5. Events of Default. Any one or more of the following shall constitute an “Event of Default” under this Agreement:

 (a) Company shall fail to pay any principal or interest due hereunder or under any Note within ten days after the date due; or 

(b) Any warranty, representation, statement, report or certificate made or delivered to Essex by Company or on Company’s behalf
hereunder shall be untrue in a material respect as of the date given or made; or 
 (c) Company shall breach or fail to comply with
any covenant in Section 5 and shall fail to cure such breach or non-compliance within ten days after Company receives notice thereof or any officer of Company becomes aware thereof; or  

(d) the occurrence of any default under any agreement or obligation of Company involving any indebtedness which results in a right by a
third party or parties, whether or not exercised, to accelerate the maturity of such indebtedness in excess of $200,000, or the occurrence of any default under any agreement or obligation of Company that could reasonably be expected to have a
material adverse effect on the Company; or 
 (e) any portion of the Company’s assets is attached or seized, or a levy is
filed against any such assets, or a judgment or judgments is/are entered for the payment of money, individually or in the aggregate, of at least $250,000 and such judgment remains unstayed for a period of ten (10) days; or 

(f) Dissolution or termination of existence of Company; or appointment of a receiver, trustee or custodian, for all or any material part
of the property of, assignment for the benefit of creditors by, or the commencement of any proceeding by or against Company under any reorganization, bankruptcy, insolvency, arrangement, dissolution or liquidation law or statute of any jurisdiction,
now or in the future in effect (except that, in the case of a proceeding commenced against Company, Company shall have sixty days after the date such proceeding was commenced to have it dismissed, provided Essex shall have no obligation to make
any Advances during such period). 

  
 5. 

 6. Remedies. 

(a) Remedies. Upon the occurrence of any Event of Default, Essex, at its option, may do any one or more of the following, subject to the
Subordination Agreement in favor of Hercules: (i) accelerate and declare all of the obligations hereunder and under any or all of the Notes to be immediately due, payable, and performable; (ii) take possession of any or all of the
Collateral wherever it may be found, and for that purpose Company hereby authorizes Essex to enter Company’s premises without interference to search for, take possession of, keep, store, or remove any of the Collateral; and (iii) dispose
of any of the Collateral, at one or more public or private sales, in lots or in bulk, for cash, exchange or other property, or on credit, and to adjourn any such sale from time to time without notice other than oral announcement at the time
scheduled for sale. All reasonable attorneys’ fees, expenses, costs, liabilities and obligations incurred by Essex with respect to the foregoing shall be added to and become part of the Obligations, and shall be due on demand. 

(b) Remedies Cumulative. In addition to the rights and remedies set forth in this Agreement, Essex shall have all the other rights and
remedies accorded a secured party under the California Uniform Commercial Code and under all other applicable laws, and under any other instrument or agreement now or in the future entered into between Essex and Company, and all of such rights and
remedies are cumulative and none is exclusive. Exercise or partial exercise by Essex of one or more of its rights or remedies shall not be deemed an election, nor bar Essex from subsequent exercise or partial exercise of any other rights or
remedies. The failure or delay of Essex to exercise any rights or remedies shall not operate as a waiver thereof, but all rights and remedies shall continue in full force and effect until all of the Obligations have been fully paid and performed.

 7. Waivers. The failure of Essex at any time or times to require Company to strictly comply with any of the provisions of this
Agreement or any other present or future agreement between Company and Essex shall not waive or diminish any right of Essex later to demand and receive strict compliance therewith. Any waiver of any default shall not waive or affect any other
default, whether prior or subsequent, and whether or not similar. None of the provisions of this Agreement or any other agreement shall be deemed to have been waived except by a specific written waiver signed by an authorized officer of Essex.
Company waives demand, protest, notice of protest and notice of default or dishonor, notice of payment and nonpayment, release, compromise, settlement, extension or renewal of any commercial paper, instrument, account, general intangible, document
or guaranty at any time held by Essex on which Company is or may in any way be liable, and notice of any action taken by Essex, unless expressly required by this Agreement. 

8. Governing Law; Jurisdiction; Venue. This Agreement and all acts and transactions hereunder and all rights and obligations of Essex
and Company shall be governed by the internal laws (and not the conflict of laws rules) of the State of California. As a material part of the consideration to Essex to enter into this Agreement, Company (i) agrees that all actions and
proceedings relating directly or indirectly to this Agreement shall, at Essex’s option, be litigated in courts located within California, and that the venue therefor shall be Santa Barbara County; (ii) consents to the jurisdiction and
venue of any such court and consents to service of process in any such action or proceeding by personal delivery or any other method permitted by law; and (iii) waives any and all rights Company may have to object to the jurisdiction of any
such court, or to transfer or change the venue of any such action or proceeding. 
 9. MUTUAL WAIVER OF JURY TRIAL. COMPANY AND ESSEX
EACH WAIVE THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED UPON, ARISING OUT OF, OR IN ANY WAY RELATING TO, THIS AGREEMENT, THE NOTES, THE WARRANT OR ANY OTHER PRESENT OR FUTURE INSTRUMENT OR AGREEMENT BETWEEN ESSEX AND COMPANY, OR ANY
CONDUCT, ACTS OR OMISSIONS OF ESSEX OR COMPANY OR ANY OF THEIR DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, ATTORNEYS OR ANY OTHER PERSONS AFFILIATED WITH ESSEX OR COMPANY, IN ALL OF THE FOREGOING CASES, WHETHER SOUNDING IN CONTRACT, TORT OR
OTHERWISE. IF THIS JURY WAIVER IS FOR ANY REASON UNENFORCEABLE, THE PARTIES AGREE TO RESOLVE ALL CLAIMS, CAUSES AND DISPUTES THROUGH JUDICIAL REFERENCE PURSUANT TO CODE OF CIVIL PROCEDURE SECTION 638 ET

  
 6. 

 
SEQ BEFORE A MUTUALLY ACCEPTABLE REFEREE SITTING WITHOUT A JURY OR, IF NO AGREEMENT ON THE REFEREE IS REACHED, BEFORE A REFEREE SELECTED BY THE PRESIDING JUDGE OF THE CALIFORNIA SUPERIOR COURT
FOR SANTA BARBARA COUNTY. THIS PROVISION SHALL NOT RESTRICT A PARTY FROM EXERCISING NONJUDICIAL REMEDIES UNDER THE CODE. 
 10.
Notices. Any notice or other communication to be given hereunder shall be in writing and shall be (as elected by the party giving such notice): (i) personally delivered; (ii) transmitted by postage prepaid registered or certified mail,
return receipt requested; (iii) deposited prepaid with a nationally recognized overnight courier service; (iv) transmitted by electronic mail via the Internet (with a copy of such transmission delivered promptly thereafter by registered or
certified mail or courier); or (v) transmitted by telecopier (with a copy of such transmission delivered promptly by registered or certified mail or courier). Unless otherwise provided herein, all notices shall be deemed to be effective on:
(a) if delivered personally or by courier, the date of receipt (or if delivery is refused, the date of such refusal); (b) if by electronic mail, the date transmitted to the appropriate electronic mail address and an appropriate return
receipt or telephone confirmation is received; (c) if by telecopier, the date transmitted to the applicable number and an appropriate answerback or telephonic confirmation is received; or (d) if transmitted by registered or certified mail,
three (3) days after the date of posting. Any notice required this Agreement shall refer to this Agreement, including the specific section under which notice is being given. Notice hereunder shall be directed to a party at the address for such
party set forth on the signature page hereof, or to such other address or to such other person as either party shall have last designated by such notice to the other party hereto. 

11. General. This Agreement and such other written agreements, documents and instruments as may be executed in connection herewith are
the final, entire and complete agreement between Company and Essex and supersede all prior and contemporaneous negotiations and oral representations and agreements, all of which are merged and integrated in this Agreement. There are no oral
understandings, representations or agreements between the parties which are not set forth in this Agreement or in other written agreements signed by the parties in connection herewith. The terms and provisions of this Agreement may not be waived or
amended, except in a writing executed by Company and a duly authorized officer of Essex. Essex may not assign, transfer or delegate any of its duties, rights or obligations under this Agreement to any third party without the prior written consent of
the Company; provided however, that Essex may, without the prior written consent of the Company, assign, transfer or grant a participation in all or any part of, or any economic interest in, Essex’s rights to make or receive payments hereunder
as long as Essex remains the sole secured party hereunder and continues to control and administer the transactions contemplated herein (including any exercise of rights and remedies hereunder). Company may not assign any rights under or interest in
this Agreement without Essex’s prior written consent. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one agreement. The transmission of a facsimile,
including in portable document format (PDF), of any original signed counterpart of this Agreement (or any amendment hereto or any other document delivered pursuant hereto) by telecopier or electronic mail shall be treated for all purposes as the
delivery of an original signed counterpart. Time is of the essence in the performance by Company of each and every obligation under this Agreement. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 7. 

 IN WITNESS WHEREOF, the parties hereto have caused this Loan and Lease Agreement to be executed
as of the date first above written. 
  

			
	 ESSEX CAPITAL CORPORATION
	  	REVANCE THERAPEUTICS, INC.
		
	 By: /s/ Ralph T.
Iannelli                                        
            
	  	By: Lauren
Silvernail                                        
            
	 Title: President
	  	Title: EVP & CFO
		
	 Address for notices:
	  	Address for notices:
		
	 Essex Capital Corporation

1486 East Valley Road

Santa Barbara, CA 93108

Attention: Ralph T. Iannelli

Facsimile: (805) 565-0993

E-mail: ralph@essexcapitalcorp.com
	  	 Revance Therapeutics, Inc.
 7555 Gateway
Boulevard
 Newark, CA 94560
 Attention: Chief Financial
Officer
 Fax: 510-742-3401
 E-mail:
lsilvernail@revance.com

  
 8. 

 EXHIBIT A-1 

DESCRIPTION OF EQUIPMENT 

IMA LIFE EQUIPMENT 
  

					
	 Phase I Equipment: Ima

			
	 Description
	  	 Model
	  	Serial
Number
	 Vial labeler
	  	Sensitive A/V	  	L1D061
	 Vial accumulation table for tray loader
	  	RT100	  	LB2266
	 Vial counter and tray loader
	  	V300	  	L5A042
			
	 Phase II Equipment: Ima
	  		  	
	 Freeze dryer vial loading/unloading machine
	  	CLU-LF12	  	EK2054
	 Freeze dryer vial loading/unloading machine
	  	CLU-LF12	  	EK2055
	 Commercial freeze dryer
	  	Lyomax 17	  	900EEF1028
	 Commercial freeze dryer
	  	Lyomax 17	  	900EEF1029
			
	 Phase III Equipment: Ima
	  		  	
	 Internal vial washing machine
	  	Vega 6	  	L7D014
	 Vial accumulation table for filler feed
	  	RT120	  	LC2057
	 Vial filling and stoppering machine
	  	Xtrema F2000	  	SL1028
	 Vial capping/crimping machine
	  	ALU400/8C	  	SA3069
	 Hopper for caps into capping machine
	  	Loading Hopper	  	F51884
	 Containment system over fill/load/cap
	  	Restricted Access Barrier System (RABS)	  	SN2004
	 External vial washer (decontamination)
	  	Hydra 300	  	L3Z047
			
	 Phase III Support Equipment: Ima
	  		  	
	 Conveyor from washer to filler
	  	Fixed Conveyor—2.5m	  	LA0482
	 Conveyor to freeze dryers
	  	Fixed Conveyor—1.5m	  	LA0476
	 Conveyor from loaders to capping machine
	  	Fixed Conveyor	  	LA0477
	 Conveyor from capper to vial washer
	  	Fixed Conveyor—2m	  	LA0478
	 Conveyor to Inspection room
	  	Fixed Conveyor	  	LA0483
	 Conveyor with swing-away gate
	  	Conveyor with swing away	  	LA0505
	 Conveyor to inspection machine
	  	Conveyor (inspection room)	  	LA0504

 EXHIBIT A-2 

DESCRIPTION OF EQUIPMENT 

SEIDENADER EQUIPMENT 
  

					
	 Description
	  	 Model
	  	Serial Number
	 Automated vial inspection machine
	  	MS-30	  	73110A/B

 EXHIBIT B 

FORM OF SECURED PROMISSORY NOTE 

 SECURED PROMISSORY NOTE 

 

			
	$            	 	, 201_

 FOR VALUE RECEIVED, the undersigned, REVANCE THERAPEUTICS, INC. (“Company”), HEREBY PROMISES
TO PAY to the order of ESSEX CAPITAL CORPORATION (“Essex”) the principal amount of
                    ($                    ), as
set forth in the Loan and Lease Agreement by and between Company and Essex dated as of                     , 2013 and as amended from time to time
(the “Loan Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to them in the Loan Agreement. 

Company further promises to pay interest on the unpaid principal amount hereof outstanding from time to time from the date hereof until
payment in full hereof at the rate (or rates) from time to time applicable to the Advances as determined in accordance with the Loan Agreement. 

This Secured Promissory Note is entitled to all of the benefits of the Loan Agreement. The Loan Agreement, among other things, contains
provisions for acceleration of the maturity of this Secured Promissory Note upon the happening of certain stated events and also for prepayments on account of principal hereof prior to the maturity of this Secured Promissory Note upon the terms and
conditions specified in the Loan Agreement. This Secured Promissory Note is also secured by the Collateral described in the Loan Agreement, and reference to the Loan Agreement is hereby made for a description of the rights of Company and Essex in
respect to such Collateral. Nothing in this Secured Promissory Note shall be deemed to limit the rights of Essex set forth in the Loan Agreement. 

Company waives presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the
execution, delivery, performance and enforcement of this Secured Promissory Note. 
 Upon the occurrence of an Event of Default, at the
option of Essex, all amounts outstanding hereunder shall become immediately due and payable. Company shall pay all reasonable fees and expenses, including, without limitation, reasonable attorneys’ fees and costs, incurred by Essex in the
enforcement or attempt to enforce any of Company’s obligations hereunder not performed when due. 
 This Secured Promissory Note shall
be governed by, and construed and interpreted in accordance with, the laws of the State of California. 
 IN WITNESS WHEREOF, Company has
caused this Secured Promissory Note to be duly executed by one of its officers thereunto duly authorized on the date hereof. 
  

			
	REVANCE THERAPEUTICS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

 EXHIBIT C 

FORM OF WARRANT 

 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR A VALID EXEMPTION THEREFROM. 

REVANCE THERAPEUTICS, INC. 

WARRANT TO PURCHASE CAPITAL STOCK 
  

			
		  	                , 201    

 No.
                     

THIS CERTIFIES THAT, for value received, ESSEX CAPITAL CORPORATION,
with its principal office at 1486 East Valley Road, 2nd Floor, Santa Barbara, California 93108, or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Revance Therapeutics, Inc., a
Delaware corporation (the “Company”), with its principal office at 7555 Gateway Boulevard, Newark, California 94560, the Exercise Shares (defined below). This Warrant is being issued in connection with [that certain Secured Promissory Note
issued as of the date hereof in the principal amount of $            (the “Principal Amount”), which note is being issued][Holder’s prior commitment to lend Company the
principal amount of $            (the “Principal Amount”)] pursuant to that certain Loan and Lease Agreement dated as of
            , 2013 (the “Effective Date”) and as amended from time to time by and between Company and Holder (the “Agreement”). 

1. DEFINITIONS. As used herein, the following terms shall have the following
respective meanings: 
 (a) “Exercise Period” shall mean the period commencing with the date of this warrant and ending on
the Expiration Date, unless terminated earlier in accordance with the terms hereof. 
 (b) “Exercise Price” shall mean the
price per Exercise Share equal to: (i) if the Warrant Stock is the Next Round Stock, 90% of the price per share at which the Next Round Stock is issued in the Next Round, (ii) if the Warrant Stock is the Company’s Series E-5 Preferred
Stock, $1.35; or (iii) if the Warrant Stock is Common Stock, 90% of the initial price per share of the Common Stock issued in the IPO; provided further that the Exercise Price is subject to further adjustment pursuant to Section 5 below.

 (c) “Exercise Shares” shall mean the number of shares of Warrant Stock equal to ten percent (10%) of the Principal
Amount divided by either (i) the 90% of the applicable Exercise Price, if the Warrant Stock is Next Round Stock of Common Stock or (ii) $1.35, if the Warrant Stock is the Company’s Series E-5 Preferred Stock, rounded down to the
nearest whole share, subject to further adjustment pursuant to Section 5 below. 

  
 1. 

 (d) “Expiration Date” shall mean the fifth anniversary of the Effective Date,
subject to early termination pursuant to Section 7 below. 
 (e) “Investor Rights Agreement” shall mean the Amended and
Restated Investor Rights Agreement dated March 29, 2013, among the Company and the investors named therein, as further amended from time to time. 

(f) “IPO” means a public offering of the Company’s Common Stock pursuant to an effective registration statement under the
Securities Act of 1933, as amended, that results in the conversion of all of the Company’s Preferred Stock into Common Stock. 

(g) “Warrant Stock” means: (i) if this Warrant is issued prior to the IPO, shares of the Company’s Preferred Stock
or any equity securities conferring the right to purchase the Company’s Preferred Stock (the “Next Round Stock”) issued in the Company’s next round of equity financing (the “Next Round”) following the Effective Date, or
shares of the Company’s Series E-5 Preferred Stock if the Next Round Stock has not been issued prior to the earlier of (A) the date of exercise of this Warrant or (B) the IPO; or (ii) if this Warrant is issued on or after the
IPO, the Company’s Common Stock. 
 2. EXERCISE OF WARRANT. The rights represented
by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the
Holder): 
 (a) An executed Notice of Exercise in the form attached hereto; 

(b) Payment of the Exercise Price either (i) in cash or by check, (ii) by cancellation of indebtedness, or (iii) through
a net exercise pursuant to Section 2.1 below; and 
 (c) This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in
the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. In the event
the Warrant is not exercised in full, the Company, at its expense, will forthwith issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder may request, exercisable for
the number of Exercise Shares equal (without giving effect to any adjustment therein) to the total number of such Exercise Shares for which this Warrant is then exercisable minus the number of Exercise Shares (without giving effect to any adjustment
therein) for which this Warrant shall have been exercised. 
 The person or entity in whose name any certificate or certificates for
Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date
of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the
close of business on the next succeeding date on which the stock transfer books are open. 

  
 2. 

 2.1 Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair
market value of one Exercise Share is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to receive shares equal to the value (as determined
below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number
of Exercise Shares computed using the following formula: 
 X = Y (A-B) 

    A 
  

			
	 Where X =
	  	the number of Exercise Shares to be issued to the Holder
		
	             Y =
	  	the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, that portion of the Warrant being canceled (at the date of such calculation)
		
	             A =
	  	the fair market value of one Exercise Share (at the date of such calculation)
		
	             B =
	  	Exercise Price (as adjusted to the date of such calculation)

 For purposes of the above calculation, prior to the IPO, the fair market value of one Exercise Share shall be
determined by the Company’s Board of Directors in good faith. If this Warrant is exercised pursuant to this Section 2.1 in connection with the Company’s IPO, the foregoing calculation shall be made on an as-converted to common stock
basis, with the fair market value per Exercise Share equal to the per share offering price to the public of the Company’s IPO. If this Warrant is exercised after the Company’s IPO, the fair market value per share shall be determined as
follows: 
 (i) if traded on a securities exchange, the fair market value shall be the average of the closing prices over a five
(5) day period ending three (3) days before the day the current fair market value of the securities is being determined;  

(ii) if actively traded over-the-counter, the fair market value shall be the average of the closing bid and asked prices quoted on the
NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined; or 

(iii) if not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the fair market value
shall be determined in good faith by the Company’s Board of Directors. 
 2.2 Exercise in Connection with Public
Offering. Notwithstanding anything to the contrary herein, if an exercise of any portion of this Warrant is to be made in connection with the Company’s IPO, the exercise of this Warrant may, at the election of the Holder, be conditioned
upon the consummation of the IPO, in which case such exercise shall be deemed to not be effective unless and until such transaction is consummated. 

  
 3. 

 2.3 Automatic Exercise. Notwithstanding anything to the contrary herein, if any portion of
this Warrant has not been exercised as of immediately prior to the expiration of the Exercise Period, and the fair market value of one Exercise Share is greater than the Exercise Price as of such time, any such unexercised portion of this Warrant
shall automatically be deemed to be exercised in full pursuant to the provisions of Section 2.1 hereof, without any further action on behalf of the Holder, immediately prior to the time this Warrant would otherwise expire pursuant to the terms
of this Warrant. 
 3. COVENANTS OF THE COMPANY. 

3.1 Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the
Company will at all times reserve and keep available, solely for issuance and delivery on the exercise of this Warrant, and free from pre-emptive rights, a number of Exercise Shares constituting Series E-5 Preferred Stock and Common Stock equal to
the total number of Exercise Shares constituting Series E-5 Preferred Stock and Common Stock from time to time issuable upon exercise of this Warrant (or, on and after the closing of the Next Round, a number of Exercise Shares constituting Next
Round Stock equal to the total number of Exercise Shares constituting Next Round Stock from time to time issuable upon exercise of this Warrant), and, from time to time, will take all steps necessary to amend its Certificate of Incorporation to
provide sufficient reserves of Exercise Shares issuable upon exercise of this Warrant. 
 3.2 Shareholder Rights. The Company
covenants and agrees that (i) in the event that the Holder receives Series E-5 Preferred Stock upon exercise of this Warrant, the Holder shall have the same rights that are afforded to other holders of the Series E-5 Preferred Stock, including
all of those rights contained in the Investor Rights Agreement applicable to Holder based upon the number of shares of Series E-5 Preferred Stock held by Holder and subject to other conditions and limitations set forth therein, provided that the
Holder joins as a party to the Investor Rights Agreement, and (ii) in the event that the Holder receives Next Round Stock upon exercise of this Warrant, the Holder shall have the same rights that are afforded to other holders of the Next Round
Stock, including all of those rights contained in the Investor Rights Agreement applicable to Holder based upon the number of shares of Next Round Stock held by Holder and subject to other conditions and limitations set forth therein, provided that
the Holder joins as a party to the Investor Rights Agreement. 
 4. REPRESENTATIONS OF
HOLDER. 
 4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring
the Warrant and the Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The Holder also represents that the entire legal and beneficial
interests of the Warrant and Exercise Shares the Holder is acquiring is being acquired for its account only. 

  
 4. 

 4.2 Securities Are Not Registered. 

(a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the
Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The
Holder has no such present intention. 
 (b) The Holder recognizes that the Warrant and the Exercise Shares must be held indefinitely
unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Exercise Shares of the Company, or to comply with any
exemption from such registration, except as may be provided for in the Investor Rights Agreement. 
 (c) The Holder is aware that
neither the Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the availability of certain current public information about the Company, the resale
following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied
and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 
 4.3 Disposition of Warrant and
Exercise Shares. 
 (a) The Company and the Holder agree that the Warrant and the Exercise Shares will be subject to the
restrictions on transfer set forth in Section 2.1 of the Investor Rights Agreement. 
 (b) The Holder understands and agrees that
all certificates evidencing the shares to be issued to the Holder may bear the following legend: 
 THESE SECURITIES HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR A VALID
EXEMPTION THEREFROM. 
 4.4 Accredited Investor Status. The Holder is an “accredited investor” as defined in Regulation
D promulgated under the Act. 
 5. ADJUSTMENT OF EXERCISE PRICE.

 5.1 Changes in Securities. In the event of changes in the outstanding Series E-5 Preferred or Common Stock of the Company by
reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, consolidation, merger, liquidations, or the like, the number and class of shares available under the Warrant
in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the  

  
 5. 

 
total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event
requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed
because of any adjustment in the number of Exercise Shares subject to this Warrant. 
 5.2 Continuation of Terms. Subject to
Section 7, upon any reorganization, consolidation or merger (and any liquidation following any such event) referred to in this Section 5, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the
shares of stock and other securities and property receivable on the exercise of this Warrant after the consummation of such reorganization, consolidation or merger, or the effective date of liquidation following any such event, as the case may be,
and shall be binding upon the issuer of any stock or other securities in such event, whether or not such person shall have expressly assumed the terms of this Warrant. 

6. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this Warrant as a
consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share.
If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting
from multiplying the then current fair market value of an Exercise Share by such fraction. 
 7. EARLY
TERMINATION. In the event of a Liquidation Event, Acquisition or Asset Transfer (as such terms are defined in the Company’s Certificate of Incorporation, as may be amended from time to time, and each, an “Acquisition
Event”), then the Company shall provide to the Holder ten (10) days advance written notice of such Acquisition Event, and this Warrant shall terminate upon the closing of such Acquisition Event, as applicable, unless exercised prior to
such closing (provided that the effective date of exercise may be the closing of such Acquisition Event). 
 8. MARKET
STAND-OFF AGREEMENT. Holder agrees that the market stand-off agreement in Section 2.11 of the Investor Rights Agreement shall apply to the Warrant and the Exercise Shares. 

9. NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to
any voting rights or other rights as a stockholder of the Company. 
 10. LOST, STOLEN,
MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which
shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual
obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

  
 6. 

 11. NOTICES, ETC. All notices and other communications
required or permitted hereunder shall be in writing and shall be sent by telex, telegram, express mail or other form of rapid communications, if possible, and if not then such notice or communication shall be mailed by first-class mail, postage
prepaid, addressed in each case to the party entitled thereto at the following addresses: (a) if to the Company, to Revance Therapeutics, Inc., Attention: Chief Financial Officer, 7555 Gateway Boulevard, Newark, CA 94560 and (b) if to the
Holder, to the address stated herein, or at such other address as one party may furnish to the other in writing. Notice shall be deemed effective on the date dispatched if by personal delivery, telecopy, telex or telegram, two days after mailing if
by express mail, or three days after mailing if by first-class mail. In the event of any Acquisition Event, the Company shall provide to the Holder ten (10) days advance notice of such Acquisition Event. 

12. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the
terms and conditions contained herein. 
 13. AMENDMENT. Any term of this Warrant may be amended or waived with the
written consent of the Company and the Holder. 
 14. GOVERNING LAW. This Warrant and all rights,
obligations and liabilities hereunder shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within the State of California without giving
effect to conflicts of laws principles. 
 [SIGNATURE PAGE FOLLOWS] 

  
 7. 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of the first date set forth above. 
  

			
	REVANCE THERAPEUTICS, INC.
		
	By:	 	 
		 	L. Daniel Browne, President and Chief Executive Officer

  
 8. 

 NOTICE OF EXERCISE 

TO: REVANCE THERAPEUTICS, INC. 

(1)  ̈ The undersigned hereby elects to purchase
            shares of             Stock of Revance Therapeutics, Inc. (the “Company”) pursuant to the
terms of the attached Warrant, and tenders herewith payment of the exercise price in full. 

       ̈ The undersigned hereby elects to purchase
            shares of             Stock of the Company pursuant to the terms of the net exercise provisions set forth in
Section 2.1 of the attached Warrant. 
 (2) Please issue a certificate or certificates representing said shares of stock in the
name of the undersigned or in such other name as is specified below: 
  

			
	____________________________	  	____________________________
	(Name)	  	____________________________
		  	(Address)

 (3) The undersigned represents that (i) the aforesaid shares are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the
Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) undersigned is experienced in
making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests;
(iv) undersigned understands that the shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration
provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they must be held
indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) undersigned is aware that the aforesaid shares may not be sold pursuant to Rule 144 adopted under the Securities Act
unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public about the Company
and the Company has not made such information available and has no present plans to do so; (vi) undersigned agrees not to make any disposition of all or any part of the aforesaid shares unless and until there is then in effect a registration
statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the Company with an opinion of counsel satisfactory to the Company,
stating that such registration is not required; and (vii) undersigned agrees to continue to be bound by the terms of the Warrant, including the market stand-off agreement in Section 8. 

 

							
	Date:                         	 		 	By:	 	  

				
		 		 	Name:	 	  

  

 EXHIBIT D 

FORM OF BILL OF SALE 

 

			
	 State of California
	  	$                   USD    
	 County of Santa Barbara
	  	________________

 BILL OF SALE 

IN CONSIDERATION of the sum of                     Dollars
($                    ), the receipt of which consideration is hereby acknowledged, REVANCE THERAPEUTICS, INC., (the “Company”), with an
address of 7555 Gateway Boulevard, Newark, CA 94560, hereby sells, assigns, transfers and delivers to ESSEX CAPITAL CORPORATION (“Essex”), with an address of 1486 East Valley Road, Santa Barbara, CA 93108, all right, title and interest in
and to the equipment and other assets listed on Exhibit A and all appurtenant rights relating thereto, including any applicable warranties from the manufacturers thereof (together, the “Assets”). Exhibit A is attached hereto and
incorporated herein by reference. 
 The Company represents and warrants to Essex that: (i) the Company is the sole and lawful owner of the Assets;
(ii) the Company is hereby transferring to Essex good and marketable title to all of the Assets, free and clear of any claim, charge, encumbrance, covenant, security interest, lien, option, pledge, rights of others, or restriction, whether
imposed by agreement, understanding, law, equity or otherwise; and (iii) all of such Assets are in good operating condition, normal wear and tear excepted. 

The Company hereby covenants that, from time to time after the delivery of this instrument, at the request of Essex and without further consideration, the
Company will do, execute and deliver all and every such further acts, deeds, conveyances, assignments and assurances as reasonably may be required more effectively to convey, transfer to and vest in Essex, any of the Assets. 

The Company will be responsible for any and all applicable sales taxes relating to the transfer of the Assets. 

This instrument is executed by, and shall be binding upon, the Company, its successors and assigns, effective immediately upon its delivery to Essex. This
instrument shall be governed by and construed in accordance with the laws of the State of California applicable to contracts made and performed in such State, excluding any laws that direct the application of another jurisdiction’s laws. 

 

							
	Dated: __________________, 201__	 	 	 		 	REVANCE THERAPEUTICS, INC.
		 		
		 	 	 		 	By:                                     
                               
		 	 	 		 	 Name:
 Title:

 EXHIBIT E 

FORM OF COMMERCIAL LEASE AGREEMENT 

 EXHIBIT F 

FORM OF LANDLORD WAIVER 

 EXHIBIT G 

ADVANCE REQUEST FORM 

 

					
	To:    	 	Essex Capital Corporation	  	Date:                              ,
20__                
		 	 1486 East Valley Road
 Santa Barbara, CA
93108
 Attention: Ralph T. Iannelli
 Facsimile:
(805) 565-0993
 E-mail: ralph@essexcapitalcorp.com
	  	

  
 Revance Therapeutics, Inc. (“Company”) hereby
requests from Essex Capital Corporation (“Essex”) an Advance in the amount of                     Dollars
($            ) on                     ,
201                    (the “Advance Date”) pursuant to the Loan and Lease Agreement between Company and Lender (the
“Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 

Attached are the relevant invoices and other supporting documents with respect to such Advance. 

Please wire funds to Company’s account as set forth below: 
  

			
		 	 Bank: Silicon Valley Bank
 Bank Address: 3003
Tasman Drive, Santa Clara, CA 95054
 ABA Number: 121140399

Account Number: 3300429603
 Account Name: Revance Therapeutics,
Inc.

 Company represents that the conditions precedent to the Advance set forth in Section 1(b) of the
Agreement are satisfied or shall be satisfied upon the making of the Advance, including the issuance of a Note and warrant on the date such Advance is made to Company. 

 

			
	REVANCE THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 SCHEDULE I 

Estimated Schedule (based on Estimated Invoice Date): Ima Life Equipment 

 

									
	 Benchmark Description
	  	Invoice #	  	Estimated
Invoice Date	  	Amount ($)	 
	 Pre-engineering Phase: pre-kick-off
	  	N/A	  	Paid	  	$	150,000	  
	 Project Kick-off / Start of Detailed engineering—Project Cost
	  	80965026	  	Paid	  	$	1,853,452	  
	 Detailed Engineering Complete / BOM order—Project Cost
	  	80965054	  	Paid	  	$	959,032	  
	 Start of Assembly of Lyophilizers—Project Cost
	  	80965094	  	31-Aug-13	  	$	1,919,785	  
	 Factory Acceptance Test Complete—Phase I
	  	N/A	  	20-Dec-14	  	$	178,499	  
	 Delivery On Site—Phase I
	  	N/A	  	14-Feb-14	  	$	59,500	  
	 Factory Acceptance Test Complete—Phase II
	  	N/A	  	10-Apr-14	  	$	1,076,644	  
	 Delivery On Site—Phase II
	  	N/A	  	5-May-14	  	$	358,881	  
	 Factory Acceptance Test Complete—Phase III
	  	N/A	  	1-Jul-14	  	$	1,586,771	  
	 Delivery On Site—Phase III
	  	N/A	  	15-Sep-14	  	$	528,924	  
	 Site Acceptance Test Complete—Project Cost
	  	N/A	  	15-Dec-14	  	$	801,560	  
	 TOTAL:
	  		  		  	$	9,473,048	  

 Estimated Schedule (based on Estimated Invoice Date): Seidenader Equipment 

 

									
	 Benchmark Decryption
	  	Invoice #	  	Estimated
Invoice Date	  	Amount ($)	 
	 Project Kick-off / Start of Detailed engineering—Project
	  	TR73110_01	  	Paid	  	$	234,838	  
	 Project Kick-off / Start of Detailed engineering—Change Orders
	  	TR73110_01.1	  	Paid	  	$	11,015	  
	 Mechanical Assembly Complete—Project
	  	TR73110_02	  	Paid	  	$	469,675	  
	 Mechanical Assembly Complete—Change Orders
	  	TR73110_02.1	  	Paid	  	$	22,030	  
	 Factory Acceptance Test Complete – Project
	  	TR73110_03	  	22-Nov-13	  	$	352,256	  
	 Factory Acceptance Test Complete—Change Orders
	  	TR73110_03.1	  	22-Nov-13	  	$	16,523	  
	 Site Acceptance Test Complete- Project
	  	N/A	  	13-Mar-14	  	$	117,419	  
	 Site Acceptance Test Complete- Change Orders
	  	N/A	  	13-Mar-14	  	$	5,508	  
	 TOTAL:
	  		  		  	$	1,229,264EX-10.22

 Exhibit 10.22 

REVANCE THERAPEUTICS, INC. 

EXECUTIVE SEVERANCE BENEFIT PLAN 

1. INTRODUCTION. This Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”) is established by
Revance Therapeutics, Inc. (the “Company”). The Plan was adopted by the Board on December 17, 2013 and will become effective without further action on the IPO Date (as defined below)(the “Effective
Date”). The Plan provides for severance benefits to the Chief Executive Officer and other executive officers and key employees of the Company designated by the Board. This document constitutes the Summary Plan Description for the Plan.

 2. DEFINITIONS. For purposes of the Plan, the following terms are defined as follows: 

(a) “Accrued Amounts” means any unpaid annual base salary accrued through the date of a Participant’s
Qualifying Termination and any accrued but unpaid vacation pay. 
 (b) “Annual Bonus” means the annual cash
bonus that a Participant is eligible to earn, if any, pursuant to the Participant’s Executive Employment Agreement with the Company, as it may be amended from time to time. 

(c) “Annual Bonus Target” means a Participant’s Annual Bonus with respect to performance for the year in
which the Qualifying Termination occurs, calculated assuming the Participant achieves the maximum possible annual target bonus percentage for that year. 

(d) “Board” means the Board of Directors of the Company. 

(e) “Cause”, as determined by the Board in its sole discretion, means: (i) such Participant’s
commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of
dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such Participant’s
unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. 

(f) “Change in Control” shall have the meaning set forth in the Company’s 2014 Equity Incentive Plan. The
definition of Change in Control is intended to conform to the definitions of “change in ownership of a corporation” and “change in ownership of a substantial portion of a corporation’s assets” provided in Treasury Regulation
Sections 1.409A-3(i)(5)(v) and (vii). 
 (g) “Change in Control Termination” means (i) a
Participant’s dismissal or discharge by the Company for a reason other than death, disability, or Cause, or (ii) a Resignation for Good Reason, either of which occurs in connection with or within twelve (12) months following the
effective date of a Change in Control, provided that any such termination is a Separation from Service. In no event will a Participant’s Separation from Service due to death, disability or Cause, or a resignation by a Participant without Good
Reason, constitute a Change in Control Termination. 
 (h) “COBRA” means the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended and any analogous provisions of applicable state law. 

  
 1. 

 (i) “Code” means the Internal Revenue Code of 1986, as amended.

 (j) “Common Stock” means the common stock of the Company. 

(k) “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 

(l) “IPO Date” means the date of the underwriting agreement between the Company and the underwriter(s) managing
the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. 
 (m)
“Monthly Annual Bonus Target” means a Participant’s Annual Bonus Target, divided by 12. 
 (n)
“Monthly Base Salary” means the Participant’s annual base salary, ignoring any decrease in annual base salary that forms the basis for a Resignation for Good Reason, as in effect on the date of the Qualifying
Termination, divided by 12. 
 (o) “Non-Change in Control Termination” means a Participant’s dismissal or
discharge by the Company resulting in a Separation from Service, for a reason other than death, disability, or Cause, other than in connection with or within twelve (12) months following the effective date of a Change in Control. In no event
will a Participant’s Separation from Service due to death, disability or Cause, or a resignation by a Participant for any reason, constitute a Non-Change in Control Termination. 

(p) “Participant” means each individual who (i) is employed by the Company as an executive officer or key
employee designated by the Board, and (ii) has received and returned a signed Participation Notice. 
 (q)
“Participation Notice” means the latest notice delivered by the Company to a Participant informing the Participant that he or she is eligible to participate in the Plan, in substantially the form of
EXHIBIT A to the Plan. 
 (r) “Plan Administrator” means the Board or any committee of
the Board duly authorized to administer the Plan. The Plan Administrator may be, but is not required to be, the Compensation Committee of the Board. The Board may at any time administer the Plan, in whole or in part, notwithstanding that the Board
has previously appointed a committee to act as the Plan Administrator. 
 (s) “Qualifying Termination” means
either a Change in Control Termination or a Non-Change in Control Termination. 
 (t) “Resignation for Good
Reason” means a Participant’s resignation from all positions the Participant then holds with the Company, resulting in a Separation from Service, within ninety (90) days after the expiration of the cure period set forth below,
provided the Participant has given the Board written notice of the occurrence of any of the following events taken without the Participant’s written consent within thirty (30) days after the first occurrence of such event and the Company
has not cured such event, to the extent curable, within thirty (30) days thereafter: 
 (i) A material reduction in the
Participant’s annual base salary, which the Participant and the Company agree is a reduction of at least fifteen percent (15%) of the Participant’s annual base salary (unless pursuant to a salary reduction program applicable generally
to the Company’s similarly situated employees); 

  
 2. 

 (ii) A material reduction in the Participant’s duties (including responsibilities
and/or authorities), provided, however, that, other than with respect to the Company’s then acting Chief Executive Officer and Chief Financial Officer, a change in job position (including a change in title) shall not be deemed a
“material reduction” in and of itself unless the Participant’s new duties are materially reduced from the prior duties; 

(iii) Relocation of the Participant’s principal place of employment to a place that increases the Participant’s one-way
commute by more than thirty-five (35) miles as compared to the Participant’s then-current principal place of employment immediately prior to such relocation; 

(iv) any failure by the Company to comply with any material provision of this Plan or any material written contractual obligation to
Participant, which (in either case) adversely affects the Participant; 
 (v) the failure of any successor-in-interest to assume a
material obligation of the Company under this Plan or material written contractual obligation to Participant, which (in either case) adversely affects the Participant. 

(u) “Separation from Service” means a “separation from service” within the meaning of Treasury
Regulations Section 1.409A-1(h), without regard to any alternative definition thereunder. 
 (v) “Severance
Multiplier” means: 
 (i) for a Participant who is the Chief Executive Officer of the Company at the time of the
Qualifying Termination, (A) fifteen (15), for a Non-Change in Control Termination, and (B) twenty-one (21), for a Change in Control Termination; and 

(ii) for a Participant who is not the Chief Executive Officer of the Company at the time of the Qualifying Termination, (A) nine
(9), for a Non-Change in Control Termination, and (B) twelve (12), for a Change in Control Termination. 
 (w)
“Severance Period” means a period of months commencing on the date of a Participant’s Qualifying Termination, with the number of months being equal to a Participant’s applicable Severance Multiplier. 

(x) “Stock Options” means outstanding stock options in the Company granted to a Participant by the governing
plan documents, grant notices and stock option agreements. 
 3. ELIGIBILITY FOR BENEFITS. 

(a) Eligibility; Exceptions to Benefits. Subject to the terms and conditions of the Plan, the Company will provide the benefits
described in Section 4 to the affected Participant. A Participant will not receive benefits under the Plan in the following circumstances, as determined by the Plan Administrator, in its sole discretion: 

  
 3. 

 (i) The Plan does not provide for duplication (in whole or in part) of benefits with any
other agreement or plan. By signing a Participation Notice, a Participant is waiving his or her rights under, and terminating those provisions of, any employment agreement or severance agreement with the Company that provide for benefits on a
Qualifying Termination in existence as of the date that the Participant signs such Participation Notice. 
 (ii) The
Participant’s employment is terminated by either the Company or the Participant for any reason other than a Qualifying Termination. 

(iii) The Participant has not entered into the Employee Proprietary Information and Inventions Agreement or any similar or successor
document (the “Proprietary Information Agreement”). 
 (iv) The Participant has failed to execute and allow to
become effective the Release (as defined and described below) within sixty (60) days following the Participant’s Separation from Service. 

(v) The Participant has failed to return all Company Property. For this purpose, “Company Property” means all
paper and electronic Company documents (and all copies thereof) created and/or received by the Participant during his or her period of employment with the Company and other Company materials and property that the Participant has in his or her
possession or control, including, without limitation, Company files, correspondence, emails, memoranda, notes, notebooks, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, research and
development information, sales and marketing information, operational and personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, without limitation, leased
vehicles, computers, computer equipment, software programs, facsimile machines, mobile telephones, servers), credit and calling cards, entry cards, identification badges and keys, and any materials of any kind that contain or embody any proprietary
or confidential information of the Company (and all reproductions thereof, in whole or in part). As a condition to receiving benefits under the Plan, a Participant must not make or retain copies, reproductions or summaries of any such Company
documents, materials or property and must make a diligent search to locate any such documents, property and information. If the Participant has used any personally owned computer, server, or e-mail system to receive, store, review, prepare or
transmit any Company confidential or proprietary data, materials or information, then within ten (10) business days after the Separation from Service, the Participant must provide the Company with a computer-useable copy of all such information
and then permanently delete and expunge such confidential or proprietary information from those systems. However, a Participant is not required to return his or her personal copies of documents evidencing the Participant’s hire, termination,
compensation, benefits and stock options and any other documentation received as a stockholder of the Company. A Participant’s failure to return Company Property that is neither confidential nor material, such as an identification badge or
calling card, will not, in and of itself, disqualify such Participant from receiving benefits under the Plan; provided, that any such items of Company Property are subsequently returned to the Company upon request. 

(vi) The Participant has failed to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution,
or investigation of any existing or future litigation, arbitrations, mediations, claims, demands, audits, government or regulatory inquiries, or other matters arising from events, acts, or failures to act that occurred during the time period in

  
 4. 

 
which the Participant was employed by the Company (including any period of employment with an entity acquired by the Company). Such cooperation includes, without limitation, being available upon
reasonable notice, without subpoena, to provide accurate and complete advice, assistance and information to the Company, including offering and explaining evidence, providing truthful and accurate sworn statements, and participating in discovery and
trial preparation and testimony. As a condition of receiving benefits under the Plan, the Participant must also promptly send the Company copies of all correspondence (for example, but not limited to, subpoenas) received by the Participant in
connection with any such legal proceedings, unless the Participant is expressly prohibited by law from so doing. The Company will reimburse the Participant for reasonable out-of-pocket expenses incurred in connection with any such cooperation
(excluding foregone wages, salary, or other compensation) within thirty (30) days after the Participant’s timely presentation of appropriate documentation thereof, in accordance with the Company’s standard reimbursement policies and
procedures, and will make reasonable efforts to accommodate the Participant’s scheduling needs. 
 (b) Termination of Benefits. A
Participant’s right to receive benefits under the Plan will terminate immediately if, at any time prior to or during the period for which the Participant is receiving benefits under the Plan, the Participant, without the prior written approval
of the Plan Administrator: 
 (i) willfully breaches a material provision of the Participant’s Proprietary Information Agreement
and/or any obligations of confidentiality, non-solicitation, non-disparagement, no conflicts or non-competition provision set forth in any other agreement between the Company and a Participant (including, without limitation, the Participant’s
employment agreement or offer letter) or under applicable law; 
 (ii) encourages or solicits any of the Company’s then current
employees to leave the Company’s employ for any reason or interferes in any other manner with employment relationships at the time existing between the Company and its then current employees; or 

(iii) induces any of the Company’s then current clients, customers, suppliers, vendors, distributors, licensors, licensees, or
other third party to terminate their existing business relationship with the Company or interferes in any other manner with any existing business relationship between the Company and any then current client, customer, supplier, vendor, distributor,
licensor, licensee, or other third party. 
 4. PAYMENTS & BENEFITS. Except as may otherwise be provided in a
Participant’s Participation Notice, in the event of a Qualifying Termination, the Company will pay the Participant the Accrued Amounts, if any, on the date of such Qualifying Termination. In addition, subject to Sections 5 and 6 and a
Participant’s continued compliance with the provisions of any agreement with the Company, including, without limitation, the Participant’s Proprietary Information Agreement, in the event of a Qualifying Termination, the Participant shall
be entitled to the payments and benefits described in this Section 4, subject to the terms and conditions of the Plan. 
 (a) Cash
Severance. 
 (i) Change in Control Termination. Upon a Change in Control Termination, the Participant
will receive as severance an amount equal to the product of (i) the sum of the Participant’s Monthly Base Salary and Monthly Annual Bonus Target, and (ii) the Participant’s applicable Severance Multiplier (the “Change
in Control Cash Severance”). The Change in Control Cash Severance will be paid in a single lump sum, less all applicable withholdings and deductions; provided, however, that no payments will be made prior to the first
business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination. 

  
 5. 

 (ii) Non-Change in Control Termination. Upon a Non-Change in
Control Termination, the Participant will receive as severance an amount equal to the product of (i) the Participant’s Monthly Base Salary, and (ii) the Participant’s applicable Severance Multiplier (the “Non-Change in
Control Cash Severance”). The Non-Change in Control Cash Severance will be paid in equal installments on the Company’s regular payroll schedule over the Severance Period, less all applicable withholdings and deductions;
provided, however, that no payments will be made prior to the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying
Termination. On the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination, the Company will pay the Participant in a lump sum the
Non-Change in Control Cash Severance that the Participant would have received on or prior to such date under the original schedule but for the delay while waiting for the 60th day in compliance
with Section 409A of the Code and the effectiveness of the Release referenced in Section 5(a) below, with the balance of the Non-Change in Control Cash Severance being paid as originally scheduled. 

(b) COBRA Benefits.  

(i) If the Participant is eligible and has made the necessary elections for continuation coverage pursuant to COBRA under a health,
dental, or vision plan sponsored by the Company, the Company will pay, as and when due directly to the COBRA carrier, the COBRA premiums necessary to continue the COBRA coverage for the Participant and his or her eligible dependents until the
earliest to occur of (i) the end of the applicable Severance Period, (ii) the date on which the Participant becomes eligible for coverage under the group health insurance plans of a subsequent employer, and (iii) the date on which the
Participant is no longer eligible for continuation coverage under COBRA (such period from the date of the Qualifying Termination through the earliest of (i) through (iii), the “COBRA Payment Period”). 

(ii) Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that the payment of COBRA premiums
hereunder is likely to result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as
amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company will instead pay the Participant, on the first day of each month of the remainder of the COBRA Payment Period, a fully
taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings and deductions. To the extent applicable, on the first business day to occur on or after the
60th day following the date of the Participant’s Qualifying Termination, the Company will make the first payment under this Section 4(b)(ii) in a lump sum equal to the aggregate amount
of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on
the original schedule. The Participant may, but is not obligated to, use such payments toward the cost of COBRA premiums. 
 (iii) If
the Participant becomes eligible for coverage under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the applicable Severance Period, the Participant must immediately notify the Company of such event, and
all payments and obligations under this section 4(b) will cease. For purposes of this Section 4(b), references to COBRA also refer to analogous provisions of state law. Any applicable insurance premiums that are paid by the Company will not
include any amounts payable by the Participant under a Code Section 125 health care reimbursement plan, which are the sole responsibility of the Participant. 

  
 6. 

 (C) Accelerated Vesting. Upon a Change in Control Termination, the vesting
and exercisability (if applicable) of all outstanding and unvested Stock Options that are held by the Participant on the effective date of the Change in Control Termination will, as of the date of the Change in Control Termination, accelerate in
full as to one hundred percent (100%) of the shares subject to the Stock Options. 
 5. CONDITIONS AND
LIMITATIONS ON BENEFITS. 
 (a) Release. To be eligible to receive any benefits under
the Plan, a Participant must sign a general waiver and release in substantially the form attached hereto as EXHIBIT B, EXHIBIT C, or EXHIBIT D, as appropriate (the
“Release”), and such release must become effective in accordance with its terms, in each case within sixty (60) days following the Qualifying Termination. The Plan Administrator, in its sole discretion, may modify the
form of the required Release to comply with applicable law, and any such Release may be incorporated into a termination agreement or other agreement with the Participant. 

(b) Prior Agreements; Certain Reductions. The Plan Administrator will reduce a Participant’s benefits under the Plan by any other
statutory severance obligations or contractual severance benefits, obligations for pay in lieu of notice, and any other similar benefits payable to the Participant by the Company that are due in connection with the Participant’s Qualifying
Termination and that are in the same form as the benefits provided under the Plan (e.g., equity award vesting credit). Without limitation, this reduction includes a reduction for any benefits required pursuant to (i) any applicable legal
requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act (the “WARN Act”), (ii) a written employment, severance or equity award agreement with the Company, (iii) any Company
policy or practice providing for the Participant to remain on the payroll for a limited period of time after being given notice of the termination of the Participant’s employment, and (iv) any required salary continuation, notice pay,
statutory severance payment, or other payments either required by local law, or owed pursuant to a collective labor agreement, as a result of the termination of the Participant’s employment. The benefits provided under the Plan are intended to
satisfy, to the greatest extent possible, and not to provide benefits duplicative of, any and all statutory, contractual and collective agreement obligations of the Company in respect of the form of benefits provided under the Plan that may arise
out of a Qualifying Termination, and the Plan Administrator will so construe and implement the terms of the Plan. Reductions may be applied on a retroactive basis, with benefits previously provided being recharacterized as benefits pursuant to the
Company’s statutory or other contractual obligations. The payments pursuant to the Plan are in addition to, and not in lieu of, any unpaid salary, bonuses or employee welfare benefits to which a Participant may be entitled for the period ending
with the Participant’s Qualifying Termination. 
 (c) Mitigation. Except as otherwise specifically provided in the Plan, a
Participant will not be required to mitigate damages or the amount of any payment provided under the Plan by seeking other employment or otherwise, nor will the amount of any payment provided for under the Plan be reduced by any compensation earned
by a Participant as a result of employment by another employer or any retirement benefits received by such Participant after the date of the Participant’s termination of employment with the Company (except as provided for in Section 5(b)).

  
 7. 

 (d) Indebtedness of Participants. To the extent permitted under applicable law, if a
Participant is indebted to the Company on the effective date of a Participant’s Qualifying Termination, the Company reserves the right to offset the payment of any benefits under the Plan by the amount of such indebtedness. Such offset will be
made in accordance with all applicable laws. The Participant’s execution of the Participation Notice constitutes knowing written consent to the foregoing. 

(e) Parachute Payments. 

(i) Except as otherwise expressly provided in an agreement between a Participant and the Company, if any payment or benefit the
Participant would receive in connection with a Change in Control from the Company or otherwise (a “Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and
(ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount. The “Reduced Amount”
will be either (A) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (B) the largest portion, up to and including the total, of the Payment, whichever amount ((A) or (B)),
after taking into account all applicable federal, state, provincial, foreign, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s receipt, on an
after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the
Payment equals the Reduced Amount, reduction will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of stock awards other than stock options; (3) cancellation of accelerated vesting
of stock options; and (4) reduction of other benefits paid to the Participant. Within any such category of Payments (that is, (1), (2), (3) or (4)), a reduction will occur first with respect to amounts that are not “deferred
compensation” within the meaning of Section 409A of the Code and then with respect to amounts that are “deferred compensation.” In the event that acceleration of vesting of stock award compensation is to be reduced, such
acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant’s applicable type of stock award (i.e., earliest granted stock awards are cancelled last). If Section 409A of the Code is not
applicable by law to a Participant, the Company will determine whether any similar law in the Participant’s jurisdiction applies and should be taken into account. 

(ii) The professional firm engaged by the Company for general tax purposes as of the day prior to the effective date of the Change in
Control shall make all determinations required to be made under this Section 5(e). If the professional firm so engaged by the Company is serving as an accountant or auditor for the individual, entity or group effecting the Change in Control,
the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such professional firm required
to be made hereunder. Any good faith determinations of the professional firm made hereunder shall be final, binding and conclusive upon the Company and the Participant. 

6. TAX MATTERS. 

(a) Application of Code Section 409A. Notwithstanding anything herein to the contrary, (i) if at the time of
Participant’s termination of employment with the Company, the Participant is a “specified employee” as defined in Section 409A of the Code and the applicable guidance and 

  
 8. 

 
regulations thereunder (collectively, “Section 409A”), and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such
termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in
such payments or benefits ultimately paid or provided to Participant) until the first business day to occur following the date that is six (6) months following Participant’s termination of employment with the Company (or the earliest date
as is permitted under Section 409A); and (ii) if any other payments of money or other benefits due to Participant hereunder could cause the application of an accelerated or additional tax under Section 409A, such payments or other
benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner, determined by the Board, that
does not cause such an accelerated or additional tax. In the event that payments under the Plan are deferred pursuant to this Section 6 in order to prevent any accelerated tax or additional tax under Section 409A, then such payments shall
be paid at the time specified under this Section 6 without any interest thereon. The Company shall consult with Participant in good faith regarding the implementation of this Section 6; provided, that neither the Company nor any of
its employees or representatives shall have any liability to Participant with respect thereto. Notwithstanding anything to the contrary herein, to the extent required by Section 409A, a termination of employment shall not be deemed to have
occurred for purposes of any provision of the Plan providing for the payment of amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of
Section 409A and, for purposes of any such provision of this Agreement, references to a “resignation,” “termination,” “termination of employment” or like terms shall mean separation from service. For purposes of
Section 409A, each payment made under the Plan shall be designated as a “separate payment” within the meaning of the Section 409A. Notwithstanding anything to the contrary herein, except to the extent any expense, reimbursement
or in-kind benefit provided pursuant to the Plan does not constitute a “deferral of compensation” within the meaning of Section 409A, (A) the amount of expenses eligible for reimbursement or in-kind benefits provided to a
Participant during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to a Participant in any other calendar year; (B) the reimbursements for expenses for which a Participant is
entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred; and (C) the right to payment or reimbursement or in-kind benefits hereunder may not
be liquidated or exchanged for any other benefit. 
 (b) Withholding. All payments and benefits under the Plan will be subject to all
applicable deductions and withholdings, including, without limitation, obligations to withhold for federal, state, provincial, foreign and local income and employment taxes. 

(c) Tax Advice. By becoming a Participant in the Plan, the Participant agrees to review with the Participant’s own tax advisors the
federal, state, provincial, local, and foreign tax consequences of participation in the Plan. The Participant will rely solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant
understands that Participant (and not the Company) will be responsible for his or her own tax liability that may arise as a result of becoming a Participant in the Plan. 

7. REEMPLOYMENT. In the event of a Participant’s reemployment by the Company during the period of time in respect of which
severance benefits have been provided (that is, benefits as a result of a Qualifying Termination), the Company, in its sole and absolute discretion, may require such Participant to repay to the Company all or a portion of such severance benefits as
a condition of reemployment. 

  
 9. 

 8. CLAWBACK; RECOVERY. All payments and severance benefits provided under
the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are
listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in the Participation Notice, as the
Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a
clawback policy will be an event giving rise to Resignation for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company. 

9. RIGHT TO INTERPRET PLAN; AMENDMENT AND
TERMINATION. 
 (a) Exclusive Discretion. The Plan Administrator will have the exclusive discretion and authority
to establish rules, forms, and procedures for the administration of the Plan and to construe and interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the
operation of the Plan, including, without limitation, the eligibility to participate in the Plan, the amount of benefits paid under the Plan and any adjustments that need to be made in accordance with the laws applicable to a Participant. The rules,
interpretations, computations and other actions of the Plan Administrator will be binding and conclusive on all persons. 
 (b) Amendment
or Termination. The Company reserves the right to amend or terminate the Plan, any Participation Notice issued pursuant to the Plan or the benefits provided hereunder at any time; provided, however, that no such amendment or termination
will apply to any Participant who would be adversely affected by such amendment or termination unless such Participant consents in writing to such amendment or termination. Any action amending or terminating the Plan or any Participation Notice will
be in writing and executed by a duly authorized officer of the Company. 
 10. NO IMPLIED EMPLOYMENT
CONTRACT. The Plan will not be deemed (i) to give any employee or other person any right to be retained in the employ of the Company, or (ii) to interfere with the right of the Company to discharge any employee or other
person at any time, with or without Cause, and with or without advance notice, which right is hereby reserved. 
 11. LEGAL
CONSTRUCTION. The Plan will be governed by and construed under the laws of the State of California (without regard to principles of conflict of laws), except to the extent preempted by ERISA. 

12. CLAIMS, INQUIRIES AND APPEALS. 

(A) Applications for Benefits and Inquiries. Any application for benefits, inquiries about the Plan or inquiries about
present or future rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or her authorized representative). The Plan Administrator is set forth in Section 14(d). 

  
 10. 

 (b) Denial of Claims. In the event that any application for benefits is denied in whole or
in part, the Plan Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant’s right to review the denial. Any electronic notice will comply with the regulations of the U.S.
Department of Labor. The notice of denial will be set forth in a manner designed to be understood by the applicant and will include the following: 

(1) the specific reason or reasons for the denial; 

(2) references to the specific Plan provisions upon which the denial is based; 

(3) a description of any additional information or material that the Plan Administrator needs to complete the review and an explanation
of why such information or material is necessary; and 
 (4) an explanation of the Plan’s review procedures and the time limits
applicable to such procedures, including a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described in Section 12(d). 

The notice of denial will be given to the applicant within ninety (90) days after the Plan Administrator receives the application, unless special
circumstances require an extension of time, in which case, the Plan Administrator has up to an additional ninety (90) days for processing the application. If an extension of time for processing is required, written notice of the extension will
be furnished to the applicant before the end of the initial ninety (90) day period. 
 The notice of extension will describe the special circumstances
necessitating the additional time and the date by which the Plan Administrator is to render its decision on the application. 
 (c)
Request for a Review. Any person (or that person’s authorized representative) for whom an application for benefits is denied, in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within
sixty (60) days after the application is denied. A request for a review will be in writing and will be addressed to: 
 Revance
Therapeutics, Inc. 
 Attn: Human Resources Director 

7555 Gateway Boulevard 
 Newark, CA
94560 
 A request for review must set forth all of the grounds on which it is based, all facts in support of the request and any other matters that the
applicant feels are pertinent. The applicant (or his or her representative) will have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments, documents, records, and other information relating to
his or her claim. The applicant (or his or her representative) will be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her claim. The review will take
into account all comments, documents, records and other information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit
determination. 

  
 11. 

 (d) Decision on Review. The Plan Administrator will act on each request for review within
sixty (60) days after receipt of the request, unless special circumstances require an extension of time (not to exceed an additional sixty (60) days), for processing the request for a review. If an extension for review is required, written
notice of the extension will be furnished to the applicant within the initial sixty (60) day period. This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator
is to render its decision on the review. The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S. Department of Labor. In the event
that the Plan Administrator confirms the denial of the application for benefits, in whole or in part, the notice will set forth, in a manner designed to be understood by the applicant, the following: 

(1) the specific reason or reasons for the denial; 

(2) references to the specific Plan provisions upon which the denial is based; 

(3) a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all
documents, records and other information relevant to his or her claim; and 
 (4) a statement of the applicant’s right to bring a
civil action under Section 502(a) of ERISA. 
 (e) Rules and Procedures. The Plan Administrator will establish rules and
procedures, consistent with the Plan and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant who wishes to submit additional information in
connection with an appeal from the denial of benefits to do so at the applicant’s own expense. 
 (f) Exhaustion of Remedies. No
legal action for benefits under the Plan may be brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 12(a), (ii) has been notified by the Plan
Administrator that the application is denied, (iii) has filed a written request for a review of the application in accordance with the appeal procedure described in Section 12(c), and (iv) has been notified that the Plan Administrator
has denied the appeal. Notwithstanding the foregoing, if the Plan Administrator does not respond to an applicant’s claim or appeal within the relevant time limits specified in this Section 12, the applicant may bring legal action for
benefits under the Plan pursuant to Section 502(a) of ERISA. 
 13. BASIS OF PAYMENTS TO
AND FROM PLAN. All benefits under the Plan will be paid by the Company. The Plan will be unfunded, and benefits hereunder will be paid only from the general assets of the Company. 

14. OTHER PLAN INFORMATION. 

(a) Employer and Plan Identification Numbers. The Employer Identification Number assigned to the Company (which is the “Plan
Sponsor” as that term is used in ERISA) by the Internal Revenue Service is 77-055-1645. The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service is 502. 

  
 12. 

 (b) Ending Date for Plan’s Fiscal Year. The date of the end of the fiscal year for
the purpose of maintaining the Plan’s records is December 31. 
 (c) Agent for the Service of Legal Process. The agent for
the service of legal process with respect to the Plan is: 
 Revance Therapeutics, Inc. 

Attn: Chief Financial Officer 
 7555
Gateway Boulevard 
 Newark, CA 94560 

(d) Plan Sponsor and Administrator. The “Plan Sponsor” and the “Plan Administrator” of the Plan is: 

Revance Therapeutics, Inc. 
 Attn:
Human Resources Director 
 7555 Gateway Boulevard 

Newark, CA 94560 
 The Plan Sponsor’s and
Plan Administrator’s telephone number is (510) 742-3400. The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan. 

15. STATEMENT OF ERISA RIGHTS. 

Participants in the Plan (which is a welfare benefit plan sponsored by Revance Therapeutics, Inc.) are entitled to certain rights and
protections under ERISA. For the purposes of this Section 15, and under ERISA, Participants are entitled to: 
 Receive Information About the Plan
and Benefits 
 (a) Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as
worksites, all documents governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security
Administration; 
 (b) Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan
and copies of the latest annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The Plan Administrator may make a reasonable charge for the copies; and 

(c) Receive a summary of the Plan’s annual financial report, if applicable. The Plan Administrator is required by law to furnish
each participant with a copy of this summary annual report. 
 Prudent Actions By Plan Fiduciaries 

In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan.
The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of each Plan Participant and their beneficiaries. No one, including a Participant’s employer, a Participant’s
union or any other person, may fire a Participant or otherwise discriminate against a Participant in any way to prevent a Participant from obtaining a Plan benefit or exercising a Participant’s rights under ERISA. 

  
 13. 

 Enforcement of Participant Rights 

If a Participant’s claim for a Plan benefit is denied or ignored, in whole or in part, a Participant has a right to know why this was done, to obtain
copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. 
 Under ERISA, there are steps a
Participant can take to enforce the above rights. For instance, if a Participant request a copy of Plan documents or the latest annual report from the Plan, if applicable, and does not receive them within thirty (30) days, the Participant may
file suit in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay the Participant up to $110 a day until the Participant receive the materials, unless the materials were not sent because of
reasons beyond the control of the Plan Administrator. 
 If a Participant has a claim for benefits that is denied or ignored, in whole or in part, the
Participant may file suit in a state or federal court. 
 If a Participant is discriminated against for asserting the Participant’s rights, the
Participant may seek assistance from the U.S. Department of Labor, or the Participant may file suit in a federal court. The court will decide who should pay court costs and legal fees. If the Participant is successful, the court may order the person
the Participant has sued to pay these costs and fees. If the Participant loses, the court may order the Participant to pay these costs and fees, for example, if it finds the Participant’s claim is frivolous. 

Assistance With Questions 
 If a Participant has any
questions about the Plan, the Participant should contact the Plan Administrator. If a Participant has any questions about this statement or about the Participant’s rights under ERISA, or if a Participant needs assistance in obtaining documents
from the Plan Administrator, the Participant should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in the telephone directory or the Division of Technical Assistance and Inquiries,
Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. A Participant may also obtain certain publications about the Participant’s rights and responsibilities under ERISA by
calling the publications hotline of the Employee Benefits Security Administration. 
 16. GENERAL PROVISIONS. 

(a) Notices. Any notice, demand or request required or permitted to be given by either the Company or a Participant pursuant to the
terms of the Plan will be in writing and will be deemed given when delivered personally, when received electronically (including email addressed to the Participant’s Company email account and to the Company email account of the Company’s
Chief Financial Officer), or deposited in the U.S. Mail, First Class with postage prepaid, and addressed to the parties, in the case of the Company, at the address set forth in Section 14(d), in the case of a Participant, at the address as set
forth in the Company’s employment file maintained for the Participant as previously furnished by the Participant or such other address as a party may request by notifying the other in writing. 

  
 14. 

 (b) Transfer and Assignment. The rights and obligations of a Participant under the Plan
may not be transferred or assigned without the prior written consent of the Company. The Plan will be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition,
consolidation or otherwise to the business formerly carried on by the Company without regard to whether or not such person or entity actively assumes the obligations hereunder. 

(c) Waiver. Any party’s failure to enforce any provision or provisions of the Plan will not in any way be construed as a waiver of
any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of the Plan. The rights granted to the parties herein are cumulative and will not constitute a waiver of any party’s right to
assert all other legal remedies available to it under the circumstances. 
 (d) Severability. Should any provision of the Plan be
declared or determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired. 

(e) Section Headings. Section headings in the Plan are included only for convenience of reference and will not be considered part of the
Plan for any other purpose. 

  
 15. 

 EXHIBIT A 

REVANCE THERAPEUTICS, INC. 

EXECUTIVE SEVERANCE BENEFIT PLAN 

PARTICIPATION NOTICE 

To: Revance Human Resources Director 
 Date:
                     
 Revance
Therapeutics, Inc. (the “Company”) has adopted the Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”). The Company is providing you this Participation Notice to inform you that
you have been designated as a Participant in the Plan. A copy of the Plan document is attached to this Participation Notice. The terms and conditions of your participation in the Plan are as set forth in the Plan and this Participation Notice, which
together constitute the Summary Plan Description for the Plan. 
 You understand that by accepting your status as a Participant in the Plan,
you are waiving your rights to receive any severance benefits on any type of termination of employment under any other contract or agreement with the Company. 

You also understand that by accepting your status as a Participant in the Plan, your stock options that have been considered to be
“incentive stock options” prior to the date hereof may cease to qualify as “incentive stock options” as a result of the vesting acceleration benefit provided in the Plan. By accepting participation, you represent that you have
either consulted your personal tax or financial planning advisor about the tax consequences of your participation in the Plan, or you have knowingly declined to do so. 

Please return a signed copy of this Participation Notice to the Company’s Human Resources Director at the Company’s offices and
retain a copy of this Participation Notice, along with the Plan document, for your records. 
  

			
		 	 REVANCE THERAPEUTICS, INC.:

 
 (Signature)

 

By:                         
                                         
                                         
              
  

Title:                         
                                         
                                         
           
  

PARTICIPANT:
  

(Signature)
  

By:                         
                                         
                                         
              

 EXHIBIT B1 

RELEASE AGREEMENT 

[EMPLOYEES AGE 40 OR OVER; INDIVIDUAL TERMINATION]

 I have reviewed, I understand, and I agree completely to the terms set forth in the Revance Therapeutics, Inc. Executive Severance
Benefit Plan (the “Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete,
final and exclusive embodiment of the entire agreement between the Company, affiliates of the Company, and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company
that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby acknowledge and
reaffirm my obligations under my Employee Proprietary Information and Inventions Agreement. 
 Except as otherwise set forth in this
Release, I hereby generally and completely release the Company and its affiliates, and its and their parents, subsidiaries, successors, predecessors and affiliates, and their partners, members, directors, officers, employees, stockholders,
shareholders, agents, attorneys, predecessors, insurers, affiliates and assigns (collectively, the “Released Parties”), of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or
are in any way related to events, acts, conduct, or omissions occurring at any time prior to or on the date I sign this Release (collectively, the “Released Claims”). The Released Claims include, but are not limited to:
(a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all claims related to my compensation or benefits, including salary,
bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company and its affiliates, or their affiliates; (c) all claims for breach of contract,
wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal,
state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with
Disabilities Act of 1990 (as amended), the federal Age Discrimination in Employment Act (as amended) (“ADEA”), the federal Employee Retirement Income Security Act of 1974 (as amended), the federal Family and Medical Leave Act
(as amended) (“FMLA”), the California Family Rights Act (as amended) (“CFRA”), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended). 

 
  

	1 	To be revised, if applicable, for states other than California. 

 Notwithstanding the foregoing, I understand that the following rights or claims are not included
in my Release (the “Excluded Claims”): (a) any rights or claims for indemnification I may have pursuant to any fully executed indemnification agreement with the Company or its affiliate to which I am a party; the
charter, bylaws, or operating agreements of the Company or its affiliate; or under applicable law; (b) any rights or claims which cannot be waived as a matter of law; or (c) any claims for breach of the Plan arising after the date that I
sign this Release. In addition, I understand that nothing in this Release prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or any other
government agency, except that I hereby waive my right to any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or
might have against the Released Parties that are not included in the Released Claims. 
 I acknowledge that I am knowingly and voluntarily
waiving and releasing any rights I may have under the ADEA, and that the consideration given under the Plan for the waiver and release in the preceding paragraphs hereof is in addition to anything of value to which I was already entitled. I further
acknowledge that I have been advised by this writing, as required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise after the date I sign this Release; (b) I should consult with an attorney
prior to signing this Release (although I may choose voluntarily not do so); (c) I have twenty-one (21) days to consider this Release (although I may choose voluntarily to sign this Release earlier); (d) I have seven (7) days
following the date I sign this Release to revoke the Release by providing written notice of my revocation to an officer of the Company; and (e) this Release will not be effective until the date upon which the revocation period has expired,
which will be the eighth day after I sign this Release. 
 In giving the releases set forth in this Release, which include claims which may
be unknown or unsuspected by me at present, I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or
suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits
under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this Release. 

I hereby represent and warrant that: (a) I have been paid all compensation owed and for all time worked; (b) I have received all the
leave and leave benefits and protections for which I am eligible pursuant to FMLA, CFRA, the Company’s policies, or applicable law; and (c) I have not suffered any on-the-job injury or illness for which I have not already filed a
workers’ compensation claim. 

 I acknowledge that to become effective, I must sign and return this Release to the Company so
that it is received not later than twenty-one (21) days following the date it is provided to me, and I must not subsequently revoke the Release. 
  

			
		 	 PARTICIPANT:
  

(Signature)
  

Printed
Name:                                        
                                         
                   
  

Date:                         
                                         
                                         
           

  

 EXHIBIT C2 

RELEASE AGREEMENT 

[EMPLOYEES AGE 40 OR OVER; GROUP TERMINATION]

 I have reviewed, I understand, and I agree completely to the terms set forth in the Revance Therapeutics, Inc. Executive Severance
Benefit Plan (the “Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete,
final and exclusive embodiment of the entire agreement between the Company, affiliates of the Company, and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company
that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby acknowledge and
reaffirm my obligations under my Employee Proprietary Information and Inventions Agreement. 
 Except as otherwise set forth in this
Release, I hereby generally and completely release the Company and its affiliates, and its and their parents, subsidiaries, successors, predecessors and affiliates, and its and their partners, members, directors, officers, employees, stockholders,
shareholders, agents, attorneys, predecessors, insurers, affiliates and assigns (collectively, the “Released Parties”), of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or
are in any way related to events, acts, conduct, or omissions occurring at any time prior to or on the date I sign this Release (collectively, the “Released Claims”). The Released Claims include, but are not limited to:
(a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all claims related to my compensation or benefits, including salary,
bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company and its affiliates, or their affiliates; (c) all claims for breach of contract,
wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal,
state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with
Disabilities Act of 1990 (as amended), the federal Age Discrimination in Employment Act (as amended) 
  

	2 	 To be revised, if applicable, for states other than California. 

 
(“ADEA”), the federal Employee Retirement Income Security Act of 1974 (as amended), the federal Family and Medical Leave Act (as amended) (“FMLA”),
the California Family Rights Act (as amended) (“CFRA”), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended). 

Notwithstanding the foregoing, I understand that the following rights or claims are not included in my Release (the “Excluded
Claims”): (a) any rights or claims for indemnification I may have pursuant to any fully executed indemnification agreement with the Company or its affiliate to which I am a party; the charter, bylaws, or operating agreements of the
Company or its affiliate; or under applicable law; (b) any rights or claims which cannot be waived as a matter of law; or (c) any claims for breach of the Plan arising after the date that I sign this Release. In addition, I understand that
nothing in this Release prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or any other government agency, except that I hereby waive my right to
any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against the Released Parties that are not included
in the Released Claims. 
 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA, and
that the consideration given under the Plan for the waiver and release in the preceding paragraphs hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as
required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release (although I may choose
voluntarily not to do so); (c) I have forty-five (45) days to consider this Release (although I may choose voluntarily to sign this Release earlier); (d) I have seven (7) days following the date I sign this Release to revoke the
Release by providing written notice of my revocation to an office of the Company; (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after I sign this Release; and
(f) I have received with this Release a written disclosure under 29 U.S. Code Section 626(f)(1)(H) that includes certain information relating to the Company’s group termination. 

In giving the releases set forth in this Release, which include claims which may be unknown or unsuspected by me at present, I acknowledge
that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her 

 
favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish
all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this
Release. 
 I hereby represent and warrant that: (a) I have been paid all compensation owed and for all time worked; (b) I have
received all the leave and leave benefits and protections for which I am eligible pursuant to FMLA, CFRA, the Company’s policies, or applicable law; and (c) I have not suffered any on-the-job injury or illness for which I have not already
filed a workers’ compensation claim. 
 I acknowledge that to become effective, I must sign and return this Release to the Company so
that it is received not later than forty-five (45) days following the date it is provided to me, and I must not subsequently revoke the Release. 
  

			
		 	 PARTICIPANT:
  

(Signature)
  

Printed
Name:                                        
                                         
                   
  

Date:                         
                                         
                                         
           

 EXHIBIT D3 

RELEASE AGREEMENT 

[EMPLOYEES UNDER AGE 40] 

I have reviewed, I understand, and I agree completely to the terms set forth in the Revance Therapeutics, Inc. Executive Severance Benefit
Plan (the “Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and
exclusive embodiment of the entire agreement between the Company, affiliates of the Company, and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company that is not
expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby acknowledge and reaffirm my
obligations under my Employee Proprietary Information and Inventions Agreement. 
 Except as otherwise set forth in this Release, I hereby
generally and completely release the Company and its affiliates, and its and their parents, subsidiaries, successors, predecessors and affiliates, and its and their partners, members, directors, officers, employees, stockholders, shareholders,
agents, attorneys, predecessors, insurers, affiliates and assigns (collectively, the “Released Parties”), of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any
way related to events, acts, conduct, or omissions occurring at any time prior to or on the date I sign this Release (collectively, the “Released Claims”). The Released Claims include, but are not limited to: (a) all
claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all claims related to my compensation or benefits, including salary, bonuses,
commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company and its affiliates, or their affiliates; (c) all claims for breach of contract, wrongful
termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state,
provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act
of 1990 (as amended), the federal Employee Retirement Income Security Act of 1974 (as amended), the federal Family and Medical Leave Act (as amended) (“FMLA”), the California Family Rights Act (as amended)
(“CFRA”), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended). 
  

 

	3 	To be revised, if applicable, for states other than California. 

 Notwithstanding the foregoing, I understand that the following rights or claims are not included
in my Release (the “Excluded Claims”): (a) any rights or claims for indemnification I may have pursuant to any fully executed indemnification agreement with the Company or its affiliate to which I am a party; the
charter, bylaws, or operating agreements of the Company or its affiliate; or under applicable law; (b) any rights or claims which cannot be waived as a matter of law; or (c) any claims for breach of the Plan arising after the date that I
sign this Release. In addition, I understand that nothing in this Release prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or any other
government agency, except that I hereby waive my right to any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or
might have against the Released Parties that are not included in the Released Claims. 
 In giving the releases set forth in this Release,
which include claims which may be unknown or unsuspected by me at present, I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims
which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and
relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims
granted in this Release. 
 I hereby represent and warrant that: (a) I have been paid all compensation owed and for all time worked;
(b) I have received all the leave and leave benefits and protections for which I am eligible pursuant to FMLA, CFRA, the Company’s policies, or applicable law; and (c) I have not suffered any on-the-job injury or illness for which I
have not already filed a workers’ compensation claim. 
 I acknowledge that to become effective, I must sign and return this Release to
the Company so that it is received not later than fourteen (14) days following the date it is provided to me. 
  

			
		 	 PARTICIPANT:
  

(Signature)
  

Printed
Name:                                        
                                         
                   
  

Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]